| Literature DB >> 33407737 |
Daniel Agustin Godoy1,2, Rafael Badenes3,4,5, Paolo Pelosi6,7, Chiara Robba8,9.
Abstract
Maintaining an adequate level of sedation and analgesia plays a key role in the management of traumatic brain injury (TBI). To date, it is unclear which drug or combination of drugs is most effective in achieving these goals. Ketamine is an agent with attractive pharmacological and pharmacokinetics characteristics. Current evidence shows that ketamine does not increase and may instead decrease intracranial pressure, and its safety profile makes it a reliable tool in the prehospital environment. In this point of view, we discuss different aspects of the use of ketamine in the acute phase of TBI, with its potential benefits and pitfalls.Entities:
Keywords: Agitation; Cooperative sedation; Ketamine; Neuroprotection; Secondary insult; Sedation; Traumatic brain injury
Mesh:
Substances:
Year: 2021 PMID: 33407737 PMCID: PMC7788834 DOI: 10.1186/s13054-020-03452-x
Source DB: PubMed Journal: Crit Care ISSN: 1364-8535 Impact factor: 9.097